The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

In myasthenia gravis, the receptors for acetylcholine at the muscle surface are destroyed or modulated by antibodies that prevent the normal reaction from occurring. The antibodies are produced by the ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular ... Blood tests are also often used to identify associated antibodies. "About 80% of patients with MG are positive" for the ...

And you have to sort of bear in mind that patients with myasthenia gravis can get tired, too. They can get fatigued. But what we're talking about is this fatigability which is, as I mentioned ...

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

What are the current treatment options when someone is newly diagnosed with myasthenia gravis? These are really exciting times, I think, for patients with myasthenia gravis. In 2017, a drug was ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

In its fourth-quarter results update, Sanofi said it had discontinued the phase 3 URSA trial of tolebrutinib in patients with moderate-to-severe myasthenia gravis, but stressed the decision was ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years.

The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Diagnosed Prevalence of Myasthenia Gravis in Adults Diagnosed Prevalence of Myasthenia ...